Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19
Elizabeth R. Mann, Madhvi Menon, Sean Knight, Joanne E. Konkel, Christopher Jagger, Tovah N. Shaw, Siddharth Krishnan, Magnus Rattray, Andrew Ustianowski, Nawar Diar Bakerly, Paul Dark, Graham M. Lord, Angela Simpson, Timothy Felton, Ling‐Pei Ho, NIHR Respiratory TRC, Marc Feldmann, CIRCO, John R. Grainger, Tracy Hussell
Abstract
-67. Longitudinal analysis revealed reversion of some immune features back to the healthy median level in patients with a good eventual outcome. These findings identify previously unappreciated alterations in the innate immune compartment of COVID-19 patients and lend support to the idea that therapeutic strategies targeting release of myeloid cells from bone marrow should be considered in this disease. Moreover, they demonstrate that features of an exaggerated immune response are present early after hospital admission suggesting immune-modulating therapies would be most beneficial at early timepoints.